FORANE Drug Patent Profile

« Back to Dashboard

When do Forane patents expire, and when can generic versions of Forane launch?

Forane is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in FORANE is isoflurane. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the isoflurane profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Forane

A generic version of FORANE was approved as isoflurane by PIRAMAL CRITICAL on September 30^th, 1994.

Summary for FORANE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	6
Patent Applications:	4,462
Drug Prices:	Drug price information for FORANE
What excipients (inactive ingredients) are in FORANE?	FORANE excipients list
DailyMed Link:	FORANE at DailyMed

See drug prices for FORANE

Recent Clinical Trials for FORANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sefako Makgatho Health Sciences University	N/A
Abant Izzet Baysal University	Phase 4
State University of New York at Buffalo	Phase 4

See all FORANE clinical trials

Pharmacology for FORANE

Drug Class	General Anesthetic
Physiological Effect	General Anesthesia

US Patents and Regulatory Information for FORANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	FORANE	isoflurane	LIQUID;INHALATION	017624-001	Approved Prior to Jan 1, 1982	AN	RX	Yes	Yes

Expired US Patents for FORANE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	FORANE	isoflurane	LIQUID;INHALATION	017624-001	Approved Prior to Jan 1, 1982
Baxter Hlthcare	FORANE	isoflurane	LIQUID;INHALATION	017624-001	Approved Prior to Jan 1, 1982

FORANE (Isoflurane) Market Dynamics, Patent Position, and Financial Trajectory

Last updated: October 16, 2026

FORANE is the legacy brand of isoflurane, a volatile inhalation anesthetic used for induction and maintenance of general anesthesia. Its commercial profile is mature and largely genericized. The product has no meaningful remaining U.S. exclusivity, no biosimilar exposure, and limited standalone financial disclosure. Revenue depends on hospital procedure volumes, generic price competition, supply reliability, and the substitution of sevoflurane, desflurane, and intravenous anesthetics.

What is FORANE and who markets isoflurane?

FORANE contains isoflurane, a halogenated ether administered through an anesthesia vaporizer. The FDA-approved product is supplied as an inhalation liquid in multiple bottle sizes and is used in operating rooms and other controlled anesthesia settings.[1]

Attribute	FORANE / isoflurane position
Active ingredient	Isoflurane
Dosage form	Volatile liquid for inhalation
Therapeutic class	General inhalation anesthetic
FDA application	NDA 017624
Original U.S. approval	1981
Administration	Vaporizer-mediated inhalation
Primary customers	Hospitals, ambulatory surgery centers, anesthesia providers
U.S. regulatory status	Prescription drug
Product type	Mature small-molecule brand with generic competition
Biosimilar relevance	None

Historical U.S. labeling identifies Baxter Healthcare Corporation as the sponsor or manufacturer of FORANE.[1] Isoflurane is also sold by multiple manufacturers and distributors under generic or local brand names. Product ownership and distribution arrangements vary by country, and the original brand should be distinguished from the broader isoflurane market.

What is the Orange Book status of FORANE?

FORANE has no commercially meaningful period of FDA exclusivity remaining. Its core approval dates from 1981, and the product’s chemical composition, route of administration, and basic pharmaceutical use are long past the term of any original U.S. patent protection.[1,2]

The FDA Orange Book is the principal source for listed patents and regulatory exclusivity associated with approved drug products. FORANE’s commercial position is not supported by an active composition-of-matter patent or a current new-drug exclusivity period.[2]

Regulatory factor	FORANE assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	None identified
Pediatric exclusivity	None identified
Active composition patent	None of commercial significance
Listed method-of-use patent	None of commercial significance
Listed formulation patent	None of commercial significance
Generic substitution risk	High
Paragraph IV exposure	Low current relevance because the core product is already mature and genericized

When does FORANE lose patent and market exclusivity?

FORANE lost practical market exclusivity decades ago. The original product’s competitive protection ended through a combination of patent expiry, age of the FDA approval, and entry by other isoflurane suppliers.

The commercial timeline is:

Period	Event	Market effect
1981	FDA approval of FORANE/isoflurane NDA 017624	U.S. commercial launch
1980s-1990s	Expansion of volatile-anesthetic use	Established hospital demand
1990s onward	Generic and regional isoflurane suppliers entered	Price competition increased
2000s onward	Sevoflurane gained share in many facilities	Isoflurane growth weakened
2010s onward	Hospital purchasing consolidated	Contract pricing intensified
Current mature phase	Demand tied to procedure volumes and supply availability	Low growth, low differentiation

Patent expiration does not eliminate all commercial barriers. Manufacturers still need compliant active pharmaceutical ingredient supply, specialized filling and packaging, quality systems, stability data, controlled distribution, and hospital procurement access. Those barriers are operational rather than patent-based.

How many patents cover FORANE?

No material active U.S. patent estate protects the basic FORANE product. Isoflurane itself is an old small molecule, and its core use as an inhaled general anesthetic is long outside the normal patent term.

Are formulation patents important for isoflurane?

Formulation protection is limited. Isoflurane is supplied as a relatively simple volatile liquid rather than as a complex drug-delivery system. Commercial differentiation is more likely to arise from:

• Bottle design and vaporizer compatibility.
• Packaging that limits evaporation and contamination.
• Manufacturing controls for purity and stability.
• Distribution reliability.
• Regulatory approvals in individual jurisdictions.

These measures can protect execution and supply quality, but they do not recreate the market exclusivity associated with a novel formulation patent.

Are method-of-use patents relevant?

Method-of-use patents have little practical importance for the established FORANE indication. The product’s approved use is general anesthesia, a longstanding clinical application. Potential claims involving specific patient populations, anesthetic protocols, or combinations would face substantial validity and infringement hurdles and would not ordinarily prevent generic isoflurane use across the broad market.

Which companies are challenging FORANE in the market?

The principal competitive threat is not a single Paragraph IV challenger. It is a dispersed generic supply base combined with alternative anesthetic products.

Key competitive categories include:

Competitor	Active ingredient or modality	Competitive effect
Generic isoflurane	Isoflurane	Direct price competition
Ultane and generic sevoflurane	Sevoflurane	Competes on recovery profile, workflow, and pediatric use
Suprane and generic desflurane	Desflurane	Competes in selected high-throughput procedures but faces environmental and cost pressure
Propofol	Intravenous anesthetic	Competes in total intravenous anesthesia and induction
Nitrous oxide	Inhaled adjunct anesthetic	Used as an adjunct rather than a direct replacement
Regional anesthesia	Non-general anesthesia technique	Reduces demand for volatile anesthetics in selected procedures

Sevoflurane has been the most important product-level competitor in many operating-room formularies. It is generally less pungent than isoflurane and is widely used for inhalational induction, particularly in pediatric anesthesia. Isoflurane retains a cost advantage in some procurement environments because it is inexpensive and potent, but cost savings can be offset by slower emergence and longer operating-room turnover in selected cases.

Desflurane has faced commercial pressure from its high acquisition cost, environmental impact, and hospital sustainability policies. That pressure can support isoflurane demand, although hospitals may shift directly to sevoflurane or intravenous anesthesia instead.

What is the FDA regulatory status of FORANE?

FORANE is an FDA-approved prescription inhalation anesthetic. Its label includes warnings relating to malignant hyperthermia susceptibility, respiratory depression, hypotension, hepatic reactions, and perioperative monitoring.[1]

The product is regulated as a conventional small-molecule drug, not as a biologic. Generic competitors generally rely on an abbreviated new drug application pathway where applicable. Because the drug is administered through a vaporizer and has a long-established clinical profile, regulatory competition is primarily associated with product quality, labeling, manufacturing compliance, and supply continuity.

There is no biosimilar pathway for FORANE. Biosimilars apply to biologic products, while isoflurane is a synthetic small molecule.

What patent litigation and Paragraph IV risks affect FORANE?

No major current U.S. patent litigation is central to FORANE’s commercial outlook. The product’s core patent estate is expired, and the market is already populated by generic or non-original suppliers.

Paragraph IV litigation is therefore less relevant than it would be for a recently approved drug. A Paragraph IV certification challenges a listed patent in connection with an abbreviated new drug application. FORANE does not have a commercially significant, unexpired patent barrier that would support a conventional branded-generic litigation cycle.[2]

The more relevant legal risks are:

• Product-liability claims involving anesthesia administration.
• Manufacturing or contamination investigations.
• Labeling disputes.
• Hospital contracting and supply agreements.
• Regulatory action involving current good manufacturing practices.
• Trademark and trade-dress disputes involving the FORANE name or packaging.

How strong is the FORANE patent estate?

FORANE’s patent estate is weak for exclusivity purposes but durable as a commercial legacy product.

Patent-estate dimension	Assessment
Composition-of-matter protection	Expired
Broad therapeutic-use protection	Expired or commercially immaterial
Formulation protection	Limited
Device or delivery protection	Limited and generally not product-exclusive
Trade-secret value	Moderate for manufacturing know-how
Regulatory moat	Low
Supply-chain moat	Moderate
Brand value	Moderate in markets with established hospital familiarity
Generic-entry resistance	Low

The strongest remaining barriers are manufacturing and supply related. Isoflurane production requires specialized chemical synthesis, purification, analytical testing, packaging, and compliance. A new entrant must also establish reliable supply to hospitals, where stockouts can create significant procurement disadvantages. These barriers can support supplier profitability even when intellectual-property protection is absent.

What is the financial trajectory for FORANE?

FORANE’s financial trajectory is best characterized as mature, declining or flat at the brand level, and exposed to generic pricing. Public company reports generally do not disclose FORANE revenue separately. Sales are typically aggregated within broader anesthesia, hospital products, pharmaceutical, or critical-care categories.[3,4]

Revenue drivers

The product’s revenue is linked to:

1. The number of surgical and procedural cases requiring general anesthesia.
2. The share of procedures using volatile anesthetics.
3. Hospital formulary decisions.
4. Relative pricing against generic isoflurane and sevoflurane.
5. Supply availability and contract wins.
6. Geographic demand in emerging markets and lower-cost health systems.

Financial pressure points

FORANE has limited ability to raise prices because the active ingredient is mature and clinically substitutable. Buyers can often choose among multiple isoflurane suppliers. Large hospital systems and group purchasing organizations increase purchasing leverage and compress gross margins.

The brand can still generate recurring cash flow because anesthesia is a consumable hospital product. Demand is replenished with each procedure, and switching costs are operational rather than clinical in many settings. A hospital may retain a familiar product because of vaporizer protocols, staff experience, inventory systems, and supplier reliability.

Margin outlook

The likely margin profile is:

Financial metric	Direction
Unit demand	Flat to modestly declining in mature markets
Net price	Downward pressure
Gross margin	Lower than during protected-brand years
Operating leverage	Limited unless manufacturing is highly efficient
Cash-flow stability	Relatively stable where supply contracts are secure
Growth potential	Primarily geographic or volume-driven
Brand premium	Narrow and vulnerable to generic substitution

FORANE is therefore more valuable as a reliable hospital supply product than as an innovation asset. Its financial value depends on efficient production, regulatory compliance, distribution reach, and portfolio integration.

How does FORANE compare with sevoflurane and desflurane?

Factor	Isoflurane / FORANE	Sevoflurane	Desflurane
Patent maturity	Very mature	Mature, with generic competition	Mature, with generic competition
Relative cost	Usually low	Usually higher	Often high
Induction profile	Less suitable for inhalational induction	Stronger pediatric and induction position	Fast emergence
Operating-room turnover	Can be slower	Intermediate to favorable	Favorable
Environmental pressure	Present but lower than desflurane	Lower than desflurane	High
Generic price pressure	High	Increasing	Increasing
Commercial growth	Low	More resilient in selected settings	Under pressure
Main advantage	Cost and familiarity	Clinical versatility	Rapid washout

FORANE’s strongest competitive position is in cost-sensitive settings where rapid emergence is less important than acquisition price and established workflow. Sevoflurane is better positioned where pediatric induction, reduced pungency, and operating-room convenience carry greater weight.

What generic launch scenarios exist for FORANE?

Because generic competition is already established, future entry would not create a single cliff event. The principal scenarios are:

• Further price erosion from additional suppliers.
• Temporary price increases during manufacturing interruptions.
• Regional shortages caused by limited qualified production capacity.
• Hospital conversion from branded FORANE to generic isoflurane.
• Substitution toward sevoflurane or propofol when clinical protocols change.
• Continued branded demand in countries where the FORANE name carries procurement or physician familiarity.

The highest commercial risk is sustained price compression. The highest upside is a supply disruption affecting competing isoflurane suppliers or a rebound in procedure volumes.

What geographic markets matter for FORANE?

North America and Western Europe are mature, procurement-driven markets. Demand growth is limited by generic competition and substitution. Emerging markets can offer better volume growth because surgical capacity, hospital infrastructure, and anesthesia access continue to expand.

Geographic performance depends on:

• Local registration status.
• Import controls for pharmaceutical chemicals.
• Hospital procurement systems.
• Domestic manufacturing capacity.
• Availability of vaporizer-compatible packaging.
• Price sensitivity.
• Presence of regional generic suppliers.

A manufacturer with broad registrations and local distribution can preserve volume even without patent protection. The competitive advantage is commercial execution, not intellectual-property exclusivity.

Key Takeaways

• FORANE is the legacy isoflurane brand, with U.S. approval dating to 1981.
• Its core patent and regulatory exclusivity have expired.
• No meaningful biosimilar risk exists because isoflurane is a small-molecule drug.
• Generic competition, hospital purchasing power, and substitution by sevoflurane constrain pricing.
• Public filings do not generally report FORANE revenue separately.
• The brand’s financial trajectory is mature, with stable procedure-linked demand but limited growth and downward price pressure.
• Manufacturing quality, supply reliability, packaging, and distribution are more important than patent protection.
• No major current Paragraph IV or patent-litigation event drives the product’s market outlook.
• The strongest opportunity is volume growth in emerging markets and supply-constrained regions.
• The principal downside is additional generic price erosion or substitution by sevoflurane, propofol, or regional anesthesia.

FAQs

Is FORANE still sold in the United States?

FORANE has historically been marketed in the United States as an FDA-approved isoflurane inhalation anesthetic. Current commercial availability can vary by manufacturer, distributor, and supply conditions.

Is FORANE the same as generic isoflurane?

Yes. FORANE is a branded product containing isoflurane. Generic isoflurane products contain the same active ingredient but may differ in manufacturer, packaging, labeling, and distribution.

Does FORANE have patent protection in Europe?

The original isoflurane composition and general anesthetic use are long past ordinary patent terms. Country-specific regulatory rights, trademarks, and manufacturing protections can differ, but they do not create broad modern exclusivity.

Why would a hospital continue using FORANE after patent expiry?

Hospitals may retain the product because of established anesthesia protocols, staff familiarity, vaporizer procedures, procurement contracts, supply reliability, and low acquisition cost.

Is isoflurane demand expected to grow?

Demand is likely to remain stable or grow modestly in procedure-expanding markets. Mature markets face low growth because of generic competition, sevoflurane substitution, intravenous anesthesia, and regional anesthesia.

References

1. U.S. Food and Drug Administration. (2011). FORANE (isoflurane, USP) inhalation liquid prescribing information. Baxter Healthcare Corporation.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. Baxter International Inc. (2013). Annual report for the fiscal year ended December 31, 2012. Baxter International Inc.

4. Piramal Enterprises Limited. (2024). Annual report 2023-2024. Piramal Enterprises Limited.